Lasa Supergenerics is currently trading at Rs. 92.25, up by 4.50 points or 5.13% from its previous closing of Rs. 87.75 on the BSE.
The scrip opened at Rs. 92.70 and has touched a high and low of Rs. 94.65 and Rs. 91.65 respectively. So far 17536 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 214.90 on 04-Jan-2018 and a 52 week low of Rs. 83.80 on 13-Mar-2018.
Last one week high and low of the scrip stood at Rs. 104.90 and Rs. 86.25 respectively. The current market cap of the company is Rs. 212.07 crore.
The promoters holding in the company stood at 38.16%, while Institutions and Non-Institutions held 0.71% and 61.13% respectively.
Lasa Supergenerics has received WHO-GMP Certificate for unit situated at Mahad issued by the office of The Commissioner, the Food and Drug Administration. The company’s entry to regulated business markets will commence shortly.
Lasa Supergenerics manufactures and distributes chemicals. The company offers veterinary API products, animal feed ingredients, and reagents for therapeutic uses.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: